Pharmaceutical Technology Europe - April 2010 - (Page 2)

P The personalised medicine marathon Although holding great potential medical advances, personalised medicine will not come to fruition overnight and business models will require long-term strategies and great flexibility. This month, Pharmaceutical Technology Europe examines the promise of personalised medicine and learns why the race to the finish line will be a marathon, not a sprint. ersonalised medicine — often defined as the right treatment for the right person at the right time — is slowly treading closer to reality and has been hailed as a potential way to avoid unnecessary treatments, reduce the number of adverse drug reactions, increase treatment efficacy and, ultimately, improve health outcomes. In the US, the market for personalised medicine is already estimated at more than $230 billion, according to a report by PricewaterhouseCoopers (PwC); however, this figure is forecast to rise by 11% annually. By 2015, it will have almost doubled in size to reach more than $450 billion. “When the Wright Brothers took flight in 1903, few could imagine that in the space of less than 70 years a man would set foot on the moon,” says the PwC report. “Similarly, we believe the 21st century will give rise to advances in genomic and proteomic science that cannot yet be envisioned, and will yield results on a similarly grand scale.” The potential promise of personalised healthcare has been fuelled by recent advances in genomics and proteomics, which have improved our understanding of the variances between individuals’ genetic profiles. This knowledge 1 CONTENTS 9 THE HUMAN GENOME 2 INTRODUCTION 11 CANCER THERAPY UPDATE 5 MORE THAN SCIENCE NEEDED 14 MANUFACTURING CHALLENGES 7 FUTURE SNP MARKET 16 TOP TECHNOLOGIES

Table of Contents for the Digital Edition of Pharmaceutical Technology Europe - April 2010

Pharmaceutical Technology Europe - April 2010
Table of Contents
Why Personalised Medicine Business Models will Require Long-Term Strategies and Great Flexibility in Order to be Successful
Science Alone Will Not Lead to Better Medicines
The Current and Future Market for SNPs
The Hype, Hope and Reality of Pharmacogenetic Tests
Unraveling the Human Genome
Progress in Molecular Diagnostics
Personalising Cancer Therapy
T Cells for Patient-Specific Cancer Treatments
Future Research Strategies for Glucocorticoid Therapy
Overcoming Manufacturing and Financial Challenges of Personalised Cell Therapies
Public-Private Partnerships Prosper
Eight Latest Technologies Showcased

Pharmaceutical Technology Europe - April 2010